Related Experiment Video
Updated: Jul 16, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder
Patrick Mbaya1, Faouzi Alam, Sindhu Ashim
1Department of Psychiatry, Laureate House, South Manchester University Hospital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK. patrickmbaya@hotmail.co.uk
Objective:
To assess cardiovascular safety profile of high dose Venlafaxine XL in patients with major depression.
Method:
Effects of high dose venlafaxine (mean 346.15 mg;) on the cardiovascular system in 37 patients with major depressive disorder were evaluated: BP, ECG (PR, QT, QRSD and QTc intervals) and heart rate.
Results:
12.5% of patients developed hypertension after starting treatment with venlafaxine. There was an association between heart rate and the dose of venlafaxine although not statistically significant. There was no association between dose of venlafaxine and PR, QT, QRSD and QTc intervals. One patient on 300 mg who was hypertensive and on other medications that may prolong QTc, had mildly prolonged QTc. However this was not clinically significant.
Conclusion:
This study of subjects on high dose venlafaxine (mean 346.15 mg; range 225-525 mg) did not demonstrate any clinical or statistically significant effects on electrocardiogram (ECG) parameters including PR, QT, QRSD and QTc interval.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: Overview
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Depressive Disorders: MDD and Dysthymia
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
